Benicar olmesartan: Phase IV data

The double-blind, placebo-controlled, U.S. Phase IV BeniVICTOR trial in 941 patients showed that once-daily Benicar met the primary endpoint of significantly reducing mean SeDBP from baseline to week 8 vs. Cozaar losartan (9.7 vs. 7.1 mmHg, p<=0.0001). Benicar also significantly reduced mean SeSBP from baseline to week 8 vs. Cozaar (13.6 vs. 9.7 mmHg, p<=0.0001). Furthermore, a significantly greater proportion of patients treated with Benicar achieved a blood pressure goal of <140/90 mmHg at week 8 vs. Cozaar (31.6% vs. 19.5%, p<0.0001). ...